Bibliographies thématiques / Ioflupano / Articles de revues
Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Ioflupano.

Articles de revues sur le sujet « Ioflupano »

Auteur : Grafiati
Publié le 9 mars 2023
Mis à jour le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Ioflupano ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Serrano Vicente, J., L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J. R. Infante de la Torre, M. L. Domínguez Grande, J. I. Rayo Madrid, R. Sánchez Sánchez et C. Durán Herrera. « Valor predictivo negativo del SPECT con Ioflupano 123I en los trastornos del movimiento ». Revista Española de Medicina Nuclear 28, no 1 (février 2009) : 2–5. http://dx.doi.org/10.1016/s0212-6982(09)70207-1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Díaz Platas, Lucía, Stefan Prado Wohlwend, Mónica Romero Otero, Alba Iniesta Medel et Luis Ramudo Cela. « Relación entre la pureza radioquímica del 123i-ioflupano y la captación extracraneal (tiroidea y parotídea) ». Ars Pharmaceutica (Internet) 56, no 4 (décembre 2015) : 225–30. http://dx.doi.org/10.4321/s2340-98942015000400006.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Puñal Riobóo, J., L. Varela Lema, A. Serena Puig et A. Ruano-Ravina. « Efectividad del 123I-ioflupano (DaTSCAN©) en el diagnóstico de síndromes parkinsonianos. Una revisión sistemática ». Revista Española de Medicina Nuclear 26, no 6 (décembre 2007) : 375–84. http://dx.doi.org/10.1157/13112366.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Durán Ferreras, Eduardo, et Andrés Durán Ferreras. « Utilidad de la SPECT con 123I-ioflupano (DaT-scan) en el parkinsonismo inducido por fármacos ». Revista de Neurología 52, no 06 (2011) : 382. http://dx.doi.org/10.33588/rn.5206.2010757.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

García Vicente, A. M., J. Vaamonde Cano, A. Soriano Castrejón, C. Martínez Delgado, P. Talavera Rubio, V. M. Poblete García, S. Ruiz Solís, S. Rodado Marina et M. Cortés Romera. « SPECT con ioflupano I-123 en la catalogación de pacientes con síndrome parkinsoniano y vasculopatía cerebral ». Revista Española de Medicina Nuclear 24, no 6 (décembre 2005) : 392–403. http://dx.doi.org/10.1016/s0212-6982(05)74184-7.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Serrano Vicente, J., L. García Bernardo, C. Durán Barquero, A. Constantino Silva, J. R. Infante de la Torre, M. L. Domínguez Grande, J. I. Rayo Madrid, R. Sánchez Sánchez et C. Durán Herrera. « Valor predictivo negativo de la SPECT con ioflupano-I-123 en los trastornos del movimiento (réplica) ». Revista Española de Medicina Nuclear 28, no 5 (septembre 2009) : 267–68. http://dx.doi.org/10.1016/j.remn.2009.05.005.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

García-Gómez, F. J., D. García-Solís, F. J. Luis-Simón, V. A. Marín-Oyaga, F. Carrillo, P. Mir et R. J. Vázquez-Albertino. « Elaboración de una plantilla de SPM para la normalización de imágenes de SPECT con 123I-Ioflupano ». Revista Española de Medicina Nuclear e Imagen Molecular 32, no 6 (novembre 2013) : 350–56. http://dx.doi.org/10.1016/j.remn.2013.02.009.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

García Vicente, A. M., J. Vaamonde Cano, V. M. Poblete García, S. Rodado Marina, M. Cortés Romera, S. Ruiz Solís, R. Ibáñez Alonso et A. Soriano Castrejón. « Utilidad de la imagen de transportadores de dopamina (SPECT cerebral con ioflupano I-123) en la valoración de los trastornos del movimiento ». Revista Española de Medicina Nuclear 23, no 4 (janvier 2004) : 245–52. http://dx.doi.org/10.1016/s0212-6982(04)72294-6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Soriano Castrejón, Angel, Ana María García Vicente, Montserrat Cortés Romera, Julia Vaamonde Cano, Sonia Rodado Marina, Victor Manuel Poblete García, Sebastián Ruiz Solís et María del Prado Talavera Rubio. « 123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders ». Brazilian Archives of Biology and Technology 48, spe2 (octobre 2005) : 115–26. http://dx.doi.org/10.1590/s1516-89132005000700017.

Texte intégral
Résumé :
123-I Ioflupane (Datscan®) presynaptic imaging has been shown to have a significant utility in the assessment of patients with movement disorders 123-I Ioflupane SPECT is able to distinguish between Parkinson’s disease (PD) and other forms of parkinsonism without degeneration of the nigrostriatal pathway, including a common movement disorder such as essential tremor, and to assess disease progression in PD and other neurodegenerative disorders involving the substantia nigra.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Antonini, Angelo, et Giorgio L. Colombo. « Il ruolo della SPECT in associazione a iofupane nella diagnosi della Malattia di Parkinson : i risultati di un’esperienza ». Farmeconomia. Health economics and therapeutic pathways 3, no 3 (15 septembre 2002) : 125–33. http://dx.doi.org/10.7175/fe.v3i3.750.

Texte intégral
Résumé :
According to the latest data, in Italy 200.000 patients are affected by the Parkinson’s Disease, and the trend is bound to go up. Generally the diagnosis, crucial in this pathology, is based on the clinic observation. But the absence of typical signs or symptoms increases the possibility of diagnostic mistakes. Ioflupane (DATSCAN ®) is a new diagnostic agent indicated for detecting loss of functional dopaminergic neuron terminals in the striatum of patients with clinically uncertain Parkinsonian Syndromes. The use of Ioflupane (DATSCAN ®) in association with the single-photon emission computed tomography (SPECT) allows to improve the diagnosis. Applying systematically this diagnostic model could cause a significant reduction in hospedalization cost, with less trouble for patients and a better quality of life. Aim of this study is to show the clinical and economic consequences of the use of Ioflupane (DATSCAN â) in association with SPECT as a new standard for the diagnosis of Parkinson’s Disease, considering the perspective of the National Heath System (NHS) and a single hospital structure.
Styles APA, Harvard, Vancouver, ISO, etc.
11

Nuvoli, Susanna, Giovanna Tanda, Maria L. Stazza, Barbara Palumbo, Viviana Frantellizzi, Giuseppe De Vincentis, Angela Spanu et Giuseppe Madeddu. « 123I-Ioflupane SPECT and 18F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases ». Current Alzheimer Research 18, no 3 (6 août 2021) : 196–207. http://dx.doi.org/10.2174/1567205018666210608112302.

Texte intégral
Résumé :
Background: Both movement (MD) and cognitive (CD) disorders can occur associated in some neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Objective: We further investigated the usefulness of 123I-Ioflupane SPECT and 18F-FDG PET combined use in patients with these disorders in the early stage. Methods: We retrospectively enrolled twenty-five consecutive patients with MD and CD clinical symptoms of recent appearance. All patients had undergone neurologic examination, neuropsychological tests, and magnetic resonance imaging. 123I-Ioflupane SPECT was performed in all cases, followed by 18F-FDG PET two weeks later. In the two procedures, both qualitative (QL) and quantitative (QN) image analyses were determined. Results: In patients with both 123I-Ioflupane SPECT and 18F-FDG PET pathologic data, associated dopaminergic and cognitive impairments were confirmed in 56% of cases. Pathologic SPECT with normal PET in 16% of cases could diagnose MD and exclude an associated CD, despite clinical symptoms. On the contrary, normal SPECT with pathologic PET in 28% of cases could exclude basal ganglia damage while confirming CD. QN 123I-Ioflupane SPECT analysis showed better performance than QL since QN correctly characterized two cases of MD with normal QL. Moreover, correct classification of normal metabolism was made only by QN analysis of 18F-FDG PET in four cases, despite suspect areas of hypometabolism at QL. Conclusion: The combined use of these imaging procedures proved a reliable diagnostic tool to accurately identify and characterize MD and CD in early stage. QN analysis was effective in supporting QL evaluation, and its routine use is suggested, especially with inconclusive QL.
Styles APA, Harvard, Vancouver, ISO, etc.
12

Warhadpande, Devdutta S., Jiayan Huo, William A. Libling, Carol Stuehm, Bijan Najafi, Scott Sherman, Hong Lei, Janet Meiling Roveda et Phillip H. Kuo. « Pilot Study for Correlation of Heart Rate Variability and Dopamine Transporter Brain Imaging in Patients with Parkinsonian Syndrome ». Sensors 22, no 13 (5 juillet 2022) : 5055. http://dx.doi.org/10.3390/s22135055.

Texte intégral
Résumé :
Background: Parkinsonian syndrome (PS) is a broad category of neurodegenerative movement disorders that includes Parkinson disease, multiple system atrophy (MSA), progressive supranuclear palsy, and corticobasal degeneration. Parkinson disease (PD) is the second most common neurodegenerative disorder with loss of dopaminergic neurons of the substantia nigra and, thus, dysfunction of the nigrostriatal pathway. In addition to the motor symptoms of bradykinesia, rigidity, tremors, and postural instability, nonmotor symptoms such as autonomic dysregulation (AutD) can also occur. Heart rate variability (HRV) has been used as a measure of AutD and has shown to be prognostic in diseases such as diabetes mellitus and cirrhosis, as well as PD. I-123 ioflupane, a gamma ray-emitting radiopharmaceutical used in single-photon emission computed tomography (SPECT), is used to measure the loss of dopaminergic neurons in PD. Through the combination of SPECT and HRV, we tested the hypothesis that asymmetrically worse left-sided neuronal loss would cause greater AutD. Methods: 51 patients were enrolled on the day of their standard of care I-123 ioflupane scan for the work-up of possible Parkinsonian syndrome. Demographic information, medical and medication history, and ECG data were collected. HRV metrics were extracted from the ECG data. I-123 ioflupane scans were interpreted by a board-certified nuclear radiologist and quantified by automated software to generate striatal binding ratios (SBRs). Statistical analyses were performed to find correlations between the HRV and SPECT parameters. Results: 32 patients were excluded from the final analysis because of normal scans, prior strokes, cardiac disorders and procedures, or cancer. Abnormal I-123 ioflupane scans were clustered using T-SNE, and one-way ANOVA was performed to compare HRV and SBR parameters. The analysis was repeated after the exclusion of patients taking angiotensin-converting enzyme inhibitors, given the known mechanism on autonomic function. Subsequent analysis showed a significant difference between the high-frequency domains of heart rate variability, asymmetry of the caudate SBR, and putamen-to-caudate SBR. Conclusion: Our results support the hypothesis that more imbalanced (specifically worse left-sided) neuronal loss results in greater AutD.
Styles APA, Harvard, Vancouver, ISO, etc.
13

Paghera, Barbara, Federico Caobelli et Raffaele Giubbini. « 123I-Ioflupane SPECT in Fahr Disease ». Journal of Neuroimaging 23, no 1 (16 mars 2011) : 157–58. http://dx.doi.org/10.1111/j.1552-6569.2011.00581.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Pahuja, Gunjan, T. N. Nagabhushan et Bhanu Prasad. « Early Detection of Parkinson’s Disease by Using SPECT Imaging and Biomarkers ». Journal of Intelligent Systems 29, no 1 (27 mars 2019) : 1329–44. http://dx.doi.org/10.1515/jisys-2018-0261.

Texte intégral
Résumé :
Abstract Precise and timely diagnosis of Parkinson’s disease is important to control its progression among subjects. Currently, a neuroimaging technique called dopaminergic imaging that uses single photon emission computed tomography (SPECT) with 123I-Ioflupane is popular among clinicians for detecting Parkinson’s disease in early stages. Unlike other studies, which consider only low-level features like gray matter, white matter, or cerebrospinal fluid, this study explores the non-linear relation between different biomarkers (SPECT + biological) using deep learning and multivariate logistic regression. Striatal binding ratios are obtained using 123I-Ioflupane SPECT scans from four brain regions which are further integrated with five biological biomarkers to increase the diagnostic accuracy. Experimental results indicate that this investigated approach can differentiate subjects with 100% accuracy. The obtained results outperform the ones reported in the literature. Furthermore, logistic regression model has been developed for estimating the Parkinson’s disease onset probability. Such models may aid clinicians in diagnosing this disease.
Styles APA, Harvard, Vancouver, ISO, etc.
15

Ceulemans, Gaetane, Douwe Verdries, Jan Versijpt, Christian Vanhove et Hendrik Everaert. « Extrastriatal uptake on 123I-ioflupane brain SPECT ». European Journal of Nuclear Medicine and Molecular Imaging 37, no 5 (4 février 2010) : 1048. http://dx.doi.org/10.1007/s00259-009-1369-5.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
16

Mouraeff, Yvan, Karim Farid, Xavier Poullias, Ana Goncalves, Slavomir Petras et Nadine Caillat-Vigneron. « Thyroid protection before 123I-ioflupane (DaTSCAN) imaging ». European Journal of Nuclear Medicine and Molecular Imaging 38, no 4 (28 janvier 2011) : 786–87. http://dx.doi.org/10.1007/s00259-010-1726-4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
17

Dellavedova, Luca, Andrea Giorgetti et Lorenzo Stefano Maffioli. « Impact of 123I-Ioflupane SPECT in Patient Management ». Clinical Nuclear Medicine 41, no 3 (mars 2016) : e154-e155. http://dx.doi.org/10.1097/rlu.0000000000001018.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
18

Sato, Kenichiro, Ayumi Hida, Masashi Kameyama, Miyako Morooka et Sousuke Takeuchi. « Reduced 123I Ioflupane Binding in Bilateral Diabetic Chorea ». Clinical Nuclear Medicine 41, no 6 (juin 2016) : 481–82. http://dx.doi.org/10.1097/rlu.0000000000001202.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
19

Lange, Catharina, Anita Seese, Sarah Schwarzenböck, Karen Steinhoff, Bert Umland-Seidler, Bernd J. Krause, Winfried Brenner et al. « CT-Based Attenuation Correction in I-123-Ioflupane SPECT ». PLoS ONE 9, no 9 (30 septembre 2014) : e108328. http://dx.doi.org/10.1371/journal.pone.0108328.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
20

Kang, Arnold, et Satoshi Minoshima. « 123I-Ioflupane SPECT Findings of Pantothenate Kinase–Associated Neurodegeneration ». Clinical Nuclear Medicine 39, no 9 (septembre 2014) : 849–51. http://dx.doi.org/10.1097/rlu.0000000000000409.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Carrasco García de León, Sira, Juan Pablo Cabello, Ramón Ortiz et Julia Vaamonde. « Parkinsonism Associated with Pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the Initial Manifestation of Sporadic Creutzfeldt-Jakob Disease ». Case Reports in Neurological Medicine 2018 (31 mai 2018) : 1–3. http://dx.doi.org/10.1155/2018/5157275.

Texte intégral
Résumé :
Sporadic Creutzfeldt-Jakob disease (sCJD) is a type of progressive, subacute encephalopathy associated with spongiform degeneration of the central nervous system. sCJD includes a broad and heterogeneous spectrum of clinical variants, but extrapyramidal symptoms and signs at disease onset were rarely reported. We describe a case of unilateral parkinsonism associated with pathological 123I-ioflupane SPECT (DaTSCAN) results as the initial manifestation of M129V subtype sCJD patient. To the best of our knowledge, only 2 cases of Creutzfeldt-Jakob disease demonstrating nigrostriatal dopaminergic deficits in vivo using DaTSCAN have been published in the literature.
Styles APA, Harvard, Vancouver, ISO, etc.
22

Baghdadi, Yaser, Se Jin Anh, Allan Brook, Renee Moadel et Leonard M. Freeman. « Unilateral Absence of the Basal Ganglia on 123I-Ioflupane DaTScan ». Clinical Nuclear Medicine 44, no 10 (octobre 2019) : 842–43. http://dx.doi.org/10.1097/rlu.0000000000002743.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
23

Petyt, G., A. Kreisler, F. Demailly, A. Olivier, L. Defebvre et F. Semah. « Undetectable specific striatal [123I]-ioflupane binding in patients with parkinsonism ». Journal of the Neurological Sciences 341, no 1-2 (juin 2014) : 167–71. http://dx.doi.org/10.1016/j.jns.2014.04.024.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
24

Hinnell, Claire, Muriel Buxton-Thomas, Naomi Sibtain et Michael Samuel. « Striatal 123I-Ioflupane SPECT abnormality in sporadic Creutzfeldt–Jakob disease ». Journal of Neurology 258, no 5 (21 décembre 2010) : 948–50. http://dx.doi.org/10.1007/s00415-010-5860-5.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Manoharan, P., S. Jamieson et R. F. Bury. « Initial clinical experience with [123I]ioflupane scintigraphy in movement disorders ». Clinical Radiology 62, no 5 (mai 2007) : 463–71. http://dx.doi.org/10.1016/j.crad.2006.10.013.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
26

Gaig, Carles, Maria José Martí, Eduardo Tolosa, Francesc Valldeoriola, Pilar Paredes, Francisco Juan Lomeña et Fernando Nakamae. « 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism ». Movement Disorders 21, no 11 (2006) : 1994–98. http://dx.doi.org/10.1002/mds.21062.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
27

Rahman, Mahmudur G. M., Muhammad M. Islam, Tetsuya Tsujikawa et Hidehiko Okazawa. « A Novel Automatic Approach for Calculation of the Specific Binding Ratio in [I-123]FP-CIT SPECT ». Diagnostics 10, no 5 (9 mai 2020) : 289. http://dx.doi.org/10.3390/diagnostics10050289.

Texte intégral
Résumé :
A fully automatic method for specific binding ratio (SBR) calculation in [123I]ioflupane single-photon emission computed tomography (SPECT) studies was proposed by creating volumes of interest of the striatum (VOIst) and reference region (VOIref) without manual handling to avoid operator-induced variability. The study involved 105 patients (72 ± 10 years) suspected of parkinsonian syndrome (PS) who underwent [123I]ioflupane SPECT. The 200 images from our previous study were used for evaluation and validation of the new program. All patients were classified into PS and non-PS groups according to the results of clinical follow-up. A trapezoidal volume of interest (VOIt) containing all striatal intensive counts was created automatically, followed by VOIst setting using the previous method. SBR values were calculated from the mean values of VOIst and VOIref determined by the whole brain outside of VOIt. The low count voxels in the VOIref were excluded using an appropriate threshold. The SBR values from the new method were compared with the previous semi-automatic method and the Tossici–Bolt (TB) method. The SBRs from the semi- and fully automatic methods showed a good linear correlation (r > 0.98). The areas under the curves (AUCs) of receiver operating characteristic analysis showed no significant difference between the two methods for both our previous (AUC > 0.99) and new (AUC > 0.95) data. The diagnostic accuracy of the two methods showed similar results (>92%), and both were better than the TB method. The proposed method successfully created the automatic VOIs and calculated SBR rapidly (9 ± 1 s/patient), avoiding operator-induced variability and providing objective SBR results.
Styles APA, Harvard, Vancouver, ISO, etc.
28

Takahashi, Masaki, Shoichi Toki, Yukitaka Yamashita et Akihiro Kaneko. « Evaluation of Early-phase Biodistribution in 123I-ioflupane SPECT ». Japanese Journal of Radiological Technology 73, no 9 (2017) : 731–36. http://dx.doi.org/10.6009/jjrt.2017_jsrt_73.9.731.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
29

Banks, Kevin P., Justin G. Peacock, Michael N. Clemenshaw et Phillip H. Kuo. « Optimizing the Diagnosis of Parkinsonian Syndromes With 123I-Ioflupane Brain SPECT ». American Journal of Roentgenology 213, no 2 (août 2019) : 243–53. http://dx.doi.org/10.2214/ajr.19.21088.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
30

Badoud, Simon, Dimitri Van De Ville, Nicolas Nicastro, Valentina Garibotto, Pierre R. Burkhard et Sven Haller. « Discriminating among degenerative parkinsonisms using advanced 123 I-ioflupane SPECT analyses ». NeuroImage : Clinical 12 (février 2016) : 234–40. http://dx.doi.org/10.1016/j.nicl.2016.07.004.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
31

Hayashi, Toshiyuki, Masahiro Mishina, Masanori Sakamaki, Yuki Sakamoto, Satoshi Suda et Kazumi Kimura. « Effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT ». Annals of Nuclear Medicine 33, no 8 (28 mai 2019) : 579–85. http://dx.doi.org/10.1007/s12149-019-01367-4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

Manoharan, P., S. Jamieson et R. Bury. « A15 Initial clinical experience with 123I ioflupane scintigraphy in movement disorders ». Nuclear Medicine Communications 26, no 1 (janvier 2005) : 76. http://dx.doi.org/10.1097/00006231-200501000-00031.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

Staff, R. T., A. D. Murray, T. S. Ahearn, C. E. Counsell, K. Taylor, K. Wilson et H. G. Gemmell. « P38 FPCIT.NET : A WEB BASED ARCHIVE FOR USE WITH 123I IOFLUPANE ». Nuclear Medicine Communications 26, no 3 (mars 2005) : 294. http://dx.doi.org/10.1097/00006231-200503000-00110.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
34

Staff, R. T., A. D. Murray, T. S. Ahearn, C. E. Counsell, K. Taylor, K. Wilson et H. G. Gemmell. « P38 FPCIT.NET : A WEB BASED ARCHIVE FOR USE WITH 123I IOFLUPANE ». Nuclear Medicine Communications 26, no 3 (mars 2005) : 294. http://dx.doi.org/10.1097/00006231-200503000-00111.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
35

Djang, D. S. W., M. J. R. Janssen, N. Bohnen, J. Booij, T. A. Henderson, K. Herholz, S. Minoshima et al. « SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0 ». Journal of Nuclear Medicine 53, no 1 (8 décembre 2011) : 154–63. http://dx.doi.org/10.2967/jnumed.111.100784.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
36

Werner, Rudolf A., Charles Marcus, Sara Sheikhbahaei, Lilja B. Solnes, Jeffrey P. Leal, Yong Du, Steven P. Rowe et al. « Visual and Semiquantitative Accuracy in Clinical Baseline 123I-Ioflupane SPECT/CT Imaging ». Clinical Nuclear Medicine 44, no 1 (janvier 2019) : 1–3. http://dx.doi.org/10.1097/rlu.0000000000002333.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
37

Samardžić, T., R. Petrović, M. Relja, S. Telarović et V. Miletić. « The achievements of I-123 ioflupane (DatSCAN) in a diagnosis of parkinsonism ». Journal of the Neurological Sciences 333 (octobre 2013) : e89. http://dx.doi.org/10.1016/j.jns.2013.07.581.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
38

Ahmed, Anwar, Juebin Huang, Kun Chen, José M. Zubeldia, Jan Booij et Vani Vijayakumar. « [123I]Ioflupane imaging in Caucasians and non-Caucasians : Are there any differences ? » Journal of the Neurological Sciences 395 (décembre 2018) : 159–63. http://dx.doi.org/10.1016/j.jns.2018.10.001.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
39

Lloyd, Jim J., George Petrides, Paul C. Donaghy, Sean J. Colloby, Johannes Attems, John T. O'Brien, Gemma Roberts et Alan J. Thomas. « A new visual rating scale for Ioflupane imaging in Lewy body disease ». NeuroImage : Clinical 20 (2018) : 823–29. http://dx.doi.org/10.1016/j.nicl.2018.09.012.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
40

Tateno, F., S. Ryuji, A. Yousuke, T. Youhei, K. Masahiko et O. Tuyoshi. « The relationship between lower urinary tractfunction and 123I-ioflupane scintigraphyin Parkinson’s disease ». Journal of the Neurological Sciences 381 (octobre 2017) : 1037. http://dx.doi.org/10.1016/j.jns.2017.08.2928.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
41

Boeve, B., T. Ferman, M. Irfan, J. Aakre, E. St Louis, M. Silber, M. Tippmann-Peikert et al. « Clinical, neuropsychiatric, and ioflupane SPECT imaging findings in REM sleep behavior disorder ». Journal of the Neurological Sciences 357 (octobre 2015) : e8. http://dx.doi.org/10.1016/j.jns.2015.08.104.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
42

Shibayama, H., K. Tokumoto, E. Fujisawa, H. Yano, K. Tajima, F. Katada, S. Sato et T. Fukutake. « For effective utilization of dat-spect with 123i-ioflupane in clinical practice ». Journal of the Neurological Sciences 357 (octobre 2015) : e249. http://dx.doi.org/10.1016/j.jns.2015.08.868.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
43

Covington, Matthew F., Scott Sherman, Denise Lewis, Hong Lei, Elizabeth Krupinski et Phillip H. Kuo. « Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging ». PLOS ONE 10, no 7 (30 juillet 2015) : e0134457. http://dx.doi.org/10.1371/journal.pone.0134457.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
44

Jenkins, Peter O., Sara De Simoni, Niall J. Bourke, Jessica Fleminger, Gregory Scott, David J. Towey, William Svensson et al. « Stratifying drug treatment of cognitive impairments after traumatic brain injury using neuroimaging ». Brain 142, no 8 (14 juin 2019) : 2367–79. http://dx.doi.org/10.1093/brain/awz149.

Texte intégral
Résumé :
Abstract Cognitive impairment is common following traumatic brain injury. Dopaminergic drugs can enhance cognition after traumatic brain injury, but individual responses are highly variable. This may be due to variability in dopaminergic damage between patients. We investigate whether measuring dopamine transporter levels using 123I-ioflupane single-photon emission computed tomography (SPECT) predicts response to methylphenidate, a stimulant with dopaminergic effects. Forty patients with moderate-severe traumatic brain injury and cognitive impairments completed a randomized, double-blind, placebo-controlled, crossover study. 123I-ioflupane SPECT, MRI and neuropsychological testing were performed. Patients received 0.3 mg/kg of methylphenidate or placebo twice a day in 2-week blocks. Subjects received neuropsychological assessment after each block and completed daily home cognitive testing during the trial. The primary outcome measure was change in choice reaction time produced by methylphenidate and its relationship to stratification of patients into groups with normal and low dopamine transporter binding in the caudate. Overall, traumatic brain injury patients showed slow information processing speed. Patients with low caudate dopamine transporter binding showed improvement in response times with methylphenidate compared to placebo [median change = −16 ms; 95% confidence interval (CI): −28 to −3 ms; P = 0.02]. This represents a 27% improvement in the slowing produced by traumatic brain injury. Patients with normal dopamine transporter binding did not improve. Daily home-based choice reaction time results supported this: the low dopamine transporter group improved (median change −19 ms; 95% CI: −23 to −7 ms; P = 0.002) with no change in the normal dopamine transporter group (P = 0.50). The low dopamine transporter group also improved on self-reported and caregiver apathy assessments (P = 0.03 and P = 0.02, respectively). Both groups reported improvements in fatigue (P = 0.03 and P = 0.007). The cognitive effects of methylphenidate after traumatic brain injury were only seen in patients with low caudate dopamine transporter levels. This shows that identifying patients with a hypodopaminergic state after traumatic brain injury can help stratify the choice of cognitive enhancing therapy.
Styles APA, Harvard, Vancouver, ISO, etc.
45

Martinez-Murcia, F. J., J. M. Górriz, J. Ramírez, M. Moreno-Caballero et M. Gómez-Río. « Parametrization of textural patterns in123I-ioflupane imaging for the automatic detection of Parkinsonism ». Medical Physics 41, no 1 (17 décembre 2013) : 012502. http://dx.doi.org/10.1118/1.4845115.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
46

Dibble, Elizabeth H., Don C. Yoo, Richard B. Noto et Joseph H. Friedman. « Atypical Parkinsonian Syndromes With Very Poor Striatal Uptake on 123I-Ioflupane SPECT Imaging ». Clinical Nuclear Medicine 40, no 2 (février 2015) : e152-e156. http://dx.doi.org/10.1097/rlu.0000000000000608.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
47

Mihăilescu, Gabriela. « Essential tremor ». Romanian Medical Journal 62, no 4 (31 décembre 2015) : 357–62. http://dx.doi.org/10.37897/rmj.2015.4.5.

Texte intégral
Résumé :
Essential tremor is a frequent disease, but rather often under-diagnosed, due to the fact that the patients with mild essential tremor don’t visit the neurologist, or due to some confusion in establishing the diagnosis in advanced stages of the disease. The clinical diagnosis is the most important, and is sustained today by imaging techniques such as Datscan using 123I-Ioflupane, used in the differential diagnosis between essential tremor and Parkinsonian syndromes. The precise and early diagnosis permit the specific, customized symptomatic treatment, taking care of al the particularities of every patient, and in case of no-response to medical treatment, neurosurgical methods are available, some of them very recent, some still in clinical trials, as well as the genetic studies in order to establish the etiology of the most frequent disease in the field of movement disorders.
Styles APA, Harvard, Vancouver, ISO, etc.
48

Lundeen, Tamara F., Matthew Covington, Elizabeth A. Krupinski, Ryan Avery, Hong Lei, Scott J. Sherman et Phillip H. Kuo. « Accuracy of Dopamine Transporter Imaging with 123I-Ioflupane in Hispanic and Non-Hispanic Patients ». Journal of Nuclear Medicine Technology 48, no 2 (11 octobre 2019) : 154–57. http://dx.doi.org/10.2967/jnmt.119.231423.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
49

Quattrone, Andrea, Rita Nisticò, Maurizio Morelli, Gennarina Arabia, Marianna Crasà, Basilio Vescio, Alessandro Mechelli, Giuseppe L. Cascini et Aldo Quattrone. « Rest Tremor Pattern Predicts DaTscan ( 123 I‐Ioflupane ) Result in Tremulous Disorders ». Movement Disorders 36, no 12 (28 septembre 2021) : 2964–66. http://dx.doi.org/10.1002/mds.28797.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
50

García-Gómez, F. J., D. García-Solís, F. J. Luis-Simón, V. A. Marín-Oyaga, F. Carrillo, P. Mir et R. J. Vázquez-Albertino. « Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane ». Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 32, no 6 (novembre 2013) : 350–56. http://dx.doi.org/10.1016/j.remnie.2013.09.003.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie